Mohn Cancer Research Laboratory

Helse Bergen - Kreft

Mohn Cancer Research Laboratory (MCRL) was established in 2009 at the Laboratory Building at Haukeland University Hospital campus by Bergen Medical Research Foundation (BMFS) and Trond Mohn

The main focus of our research is to identify the genetic and molecular mechanisms that influence the risk of various types of cancer, as well as the mechanisms that have impact on treatment results of cancer patients.

Researchers at the laboratory work with the following issues:

   ● Somatic mutations that make cancer cells resistant to treatment.

   ● Germline factors that influence the risk of cancer and result in different clinical expressions and different degrees of side effects during treatment.

   ● Hormones and their role in cancer development and treatment of various hormone-sensitive cancers.

Research is mainly focused on cancer arising in the breast, ovaries, testes, prostate and the gastrointestinal tract as well as on malignant melanomas.

Mohn Cancer Research Laboratory is a modern facility, fully equipped with state of the art technology for translational cancer research, including an in-house massive parallel sequencing facility, cell culture facilities and infrastructure for all types of molecular analyses.

MCRL has scalable, dedicated servers and storage domains directly linked to our in-house sequencing infrastructure, within the frameworks of the IT-departments at the University of Bergen and Haukeland University Hospital.




Norwegian Cancer Genomics Consortium

Molecular Genetics Group

Cancer Genome Project ved Wellcome Trust Sanger Institute



We are located at the Laboratory Building, floor 1M, Haukeland University Hospital campus.

New Grants from the Norwegian Research Council
Genetic analyses process

Two New Grants from the Norwegian Research Council for the research groups at Mohn cancer laboratory

In December 2018, professor Per Eystein lønning and senior researcher Stian Knappskog each received a new research grant of 10 mill NOK from the Norwegian Research Council under the FRIMEDBIO program. Since only 5-10% of all applications to this program are funded, we are very happy that two groups...

Cancer cell

New K.G. Jebsen Centre for Genome-Directed Therapy in Cancer

Professor Per Eystein Lønning and his research team will map tumour genes for better and tailor made chemotherapy.